GLP-1 Vitamin B12 Deficiency: Who's at Risk and How Supplementation Works

Why B12 Comes Up With GLP-1 Medications

Fatigue, brain fog and tingling hands are common complaints during rapid weight loss, and vitamin B12 is one of the nutrients people wonder about. The concern is reasonable, but it is worth being precise about how much is actually known.

A 2026 narrative review in Clinical Obesity searched the literature from 2019 to 2025 and found only six studies that measured nutritional outcomes in adults on GLP-1 receptor agonists. Vitamin D and iron problems were the most consistent signals; thiamine and cobalamin (B12) deficits appeared to increase over time. The authors stressed that the data were mainly observational and that causality could not be established. A second 2026 review in Obesity Pillars reached a similar conclusion: most abnormalities reported so far are subclinical, and risk depends heavily on the individual.

How Your Body Absorbs B12

Vitamin B12 absorption is unusually complicated. Stomach acid and enzymes first release B12 from the proteins in food. Parietal cells in the stomach lining produce intrinsic factor, a protein that binds the freed B12. The B12-intrinsic factor complex then travels to the end of the small intestine (the terminal ileum), where specific receptors take it up.

Break a link in this chain and less B12 reaches your blood. There is also a second, much less efficient route: about 1% of a large B12 dose is absorbed by passive diffusion, without intrinsic factor. That backup route is why high-dose oral supplements can work even when normal absorption is impaired.

What GLP-1 Medications Might Change

There are several plausible ways GLP-1 therapy could affect B12 status:

• Eating less overall. Appetite suppression often means smaller portions of meat, fish, eggs and dairy, the main natural sources of B12.
• Food aversions and nausea. Some people stop eating protein-rich foods they used to tolerate, and prolonged vomiting reduces intake further.
• Slower gastric emptying. This is a core effect of the drug class, though its effect on B12 absorption has not been measured directly.

What about stomach acid? Native GLP-1 does act on the stomach: in a 1993 study of eight healthy volunteers, an intravenous GLP-1 infusion reduced post-meal acid secretion by about 43%. But that was a short infusion of the natural hormone, not a weekly medication, and no published study has measured acid output or intrinsic factor in people taking semaglutide or tirzepatide. Treat the "acid suppression" explanation as a hypothesis, not an established fact.

Who Faces Higher Risk?

Most of the well-documented risk factors have nothing to do with GLP-1 medications themselves, but they often coexist with them.

Long-term metformin use. In the Diabetes Prevention Program Outcomes Study, each additional year of metformin use was associated with about a 13% higher risk of B12 deficiency. Many people who start a GLP-1 medication for type 2 diabetes have taken metformin for years.

Acid-reducing medications. In a large case-control study published in JAMA, a 2-year or longer supply of proton pump inhibitors was associated with 1.65 times the odds of B12 deficiency; H2 blockers carried a smaller increase.

Age over 50. Atrophic gastritis becomes more common with age and reduces the release of B12 from food. This is why adults over 50 are generally advised to get much of their B12 from fortified foods or supplements, which contain free B12.

Plant-based diets. B12 occurs naturally only in animal foods. If you are vegetarian or vegan and now eating less, a reliable B12 source matters even more.

Prior bariatric surgery or GI disease. People with a history of gastric surgery, pernicious anemia or Crohn's disease affecting the ileum are at substantially higher risk regardless of medication.

Reading Your B12 Labs

Serum B12 is the usual first test, but it is an imperfect marker. Levels below about 200 pg/mL (around 148 pmol/L) are generally considered deficient, while values in the low-normal range can still hide a functional shortage.

Methylmalonic acid (MMA) and homocysteine help clarify borderline results. Both rise when cells lack B12. Homocysteine above roughly 15 μmol/L is considered elevated, but it is less specific because folate deficiency, kidney function and genetics also affect it.

There is no formal guideline yet on routine B12 testing for GLP-1 users. Both 2026 reviews suggest individualised assessment, with lab evaluation for people at higher risk. If you have any of the risk factors above, it is reasonable to ask your clinician whether a baseline test makes sense.

Supplement Forms: What the Evidence Shows

High-dose oral B12. A 2018 Cochrane review found low-quality evidence that oral B12 at 1,000-2,000 mcg per day normalised serum B12 about as effectively as intramuscular injections over the short term. The passive-diffusion route explains why.

Sublingual tablets. These are popular because they "bypass the stomach," but much of the dose is swallowed anyway. In a small randomised trial, 500 mcg taken sublingually or swallowed raised B12 levels equally over four weeks. Sublingual is a fine choice if you prefer it, not a superior one.

Methylcobalamin vs cyanocobalamin. Both forms are converted inside cells into the active coenzymes. There is no good clinical evidence that methylcobalamin works better for correcting deficiency; cyanocobalamin is the form used in most trials.

Injections. Intramuscular B12 is the standard choice when deficiency is severe, when neurological symptoms are present, or when there is pernicious anemia. Dosing schedules are set by a clinician.

Timing. There is no evidence that B12 needs to be separated from an injectable GLP-1 dose. If you take oral semaglutide tablets, follow the label instructions: take the tablet on an empty stomach with no more than 120 mL (4 oz) of plain water, and wait at least 30 minutes before eating, drinking or taking other oral medications, including supplements.

Symptoms Worth Mentioning to Your Clinician

B12 deficiency usually develops slowly because the liver stores several years' worth. Early signs are vague: fatigue, low mood, poor concentration. Later signs include a sore, smooth tongue, pins and needles in the hands or feet, balance problems and memory changes.

Many of these overlap with the side effects of rapid weight loss, which is exactly why they should not be self-diagnosed. Neurological damage from B12 deficiency can become permanent if treatment is delayed, so persistent numbness or balance problems deserve prompt medical evaluation rather than a wait-and-see approach. Severe, prolonged nausea or vomiting can also cause other deficiencies, such as thiamine, which need urgent attention.

A Practical, Conservative Approach

• Know your risk factors. Metformin, PPIs or H2 blockers, age over 50, a plant-based diet and prior GI surgery all raise the stakes.
• Protect protein and B12 foods. When appetite is low, prioritise eggs, dairy, fish, meat or fortified foods at the meals you do eat.
• Ask about testing. A baseline B12 level is reasonable if you have risk factors; your clinician can decide on follow-up.
• Choose a proven form. If supplementation is recommended, a standard oral dose is usually enough; injections are for clinician-directed treatment.
• Don't mask the problem. High-dose folic acid can hide the anemia of B12 deficiency while nerve damage continues, so avoid self-prescribing large folate doses.

The Bottom Line

GLP-1 medications may contribute to low B12 indirectly, mainly through reduced food intake, but the direct evidence is still thin. The best-established risks are metformin, long-term acid suppression, older age and diet. Oral B12 is effective for most people, injections are reserved for more severe cases, and any neurological symptom deserves a prompt conversation with your clinician.